Spectral Medical To Present At Microcap Rodeo's Annual Winter Wonderland- Best Ideas Virtual Investor Conference Today

TORONTO, ON / ACCESSWIRE / February 22, 2023 / Spectral Medical Inc. ("Spectral" or the "Company") (TSX:EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that it has been invited to present at MicroCap Rodeo's Third Annual Winter Wonderland - Best Ideas Virtual Investor conference, which is being held virtually on February 21^st - 24^th, 2023.

Chris Seto, Chief Executive Officer of Spectral Medical, and Dr. John Kellum, Chief Medical Officer of Spectral Medical, are scheduled to present today, Wednesday, February 22, 2023 at 4:30 p.m. Eastern Time. Management will also host one-on-one meetings with qualified investors throughout the conference.

To receive additional information, request an invitation or to schedule a one-on-one meeting, please email [email protected].

Investors can register here.

About the MicroCap Rodeo Winter Wonderland Best Ideas Conference

The MicroCap Rodeo is back with its Third Annual Winter Wonderland Best Ideas Conference. This conference is a virtual conference that brings you the top 37 best ideas. Qualified institutional investors recommended each of the 37 companies represented as one of their best ideas. Those of you who attended the 2019 MicroCap Rodeo in Austin, Texas, know that we're focused on alpha.

About Spectral

Spectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ ("PMX"). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis.

PMX is approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 340,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. In July 2022, the U.S. FDA granted Breakthrough Device Designation for PMX for the treatment of endotoxemic septic shock. Approximately 330,000 patients are diagnosed with septic shock in North America each year.

Spectral is listed on the Toronto Stock Exchange under the symbol EDT. For more information please visit www.spectraldx.com.

Forward-looking statement

Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.

For further information, please contact:

Ali Mahdavi
Capital Markets & Investor Relations
Spinnaker Capital Markets Inc.
416-962-3300
[email protected]

David Waldman/Natalya Rudman
US Investor Relations
Crescendo Communications, LLC
212-671-1020
[email protected]

Blair McInnis
CFO
Spectral Medical Inc.
416-626-3233
[email protected]

SOURCE: Spectral Medical Inc.